Abstract
P. aeruginosa (PA) is a common pathogen in patients with bronchiectasis and is associated with worse clinical outcomes.
Aim of this study is to describe the frequency and risk factors of antibiotic resistance development in patients with bronchiectasis colonized by PA.
This was an observational, prospective, multicenter study of consecutive adult outpatients with bronchiectasis attending the Bronchiectasis Clinic at three different University Hospitals from 2013 to 2017.
Out of 740 bronchiectasis patients, 122 (mean age 66 yrs; 43% males) presented at least 2 PA isolations. At the first isolation, 21 (17%) PA isolates were resistant to ciprofloxacin, 8 (7%) to gentamicin and 8 (7%) to piperacillin/tazobactam, 6 (5%) to ceftazidime, 5 (4%) to meropenem, 4 (3%) to tobramicin, and 1 (1%) to amikacin and colistin, while 11 (9%) isolates were multi-drug resistant (MDR). During a mean (SD) follow-up time of 36 (33) months, 23 (23%) PA isolates acquired PA resistance to ciprofloxacin, 18 (16%) to gentamicin, 14 (12%) to amikacin, 10 (9%) to ceftazidime, 9 (8%) to piperacillin/tazobactam and 9 (8%) to meropenem, 2 (2%) to tobramicin, and 3 (2%) to colistin, while 12 (11%) isolates became MDR. The number of exacerbations and hospitalizations between the 2 PA isolates were significantly higher in those who developed resistance to at least 1 antibiotic class (p-value 0.048 and 0.036, respectively).
In conclusion, in three hospitals in Italy and Spain fluoroquinolones resistance is developed in almost one out of four patients with bronchiectasis. Resistance acquisition seems to be associated with a higher number of exacerbations and hospitalizations.
Footnotes
Cite this article as: European Respiratory Journal 2018 52: Suppl. 62, PA5314.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2018